Apixaban

Last Updated: 09/19/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 6675 publications

Cost comparison between apixaban and low molecular weight heparin (LMWH) among venous thromboembolism (VTE) patients with cancer.

Cost comparison between apixaban and low molecular weight heparin (LMWH) among venous thromboembolism (VTE) patients with cancer.

Journal: Current medical research and opinion

Published: September 04, 2026

Oral Anticoagulants in Patients With Atrial Fibrillation and Advanced CKD Not Requiring Dialysis.

Oral Anticoagulants in Patients With Atrial Fibrillation and Advanced CKD Not Requiring Dialysis.

Journal: JAMA network open

Published: September 04, 2026

Severe Supratherapeutic international normalized ratio (INR) following concomitant Ribociclib and warfarin therapy.

Severe Supratherapeutic international normalized ratio (INR) following concomitant Ribociclib and warfarin therapy.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: September 04, 2026

Anticoagulation in Advanced Chronic Kidney Disease: Navigating Uncertainty.

Anticoagulation in Advanced Chronic Kidney Disease: Navigating Uncertainty.

Journal: Turkish journal of haematology : official journal of Turkish Society of Haematology

Published: September 01, 2026

Apixaban Dose Selection in Kidney Failure: Reconciling Pharmacokinetics and Clinical Outcomes.

Apixaban Dose Selection in Kidney Failure: Reconciling Pharmacokinetics and Clinical Outcomes.

Journal: The Annals of pharmacotherapy

Published: August 31, 2026

Splenic Vein Thrombosis Complicating Hypertriglyceridemia-Induced Acute Pancreatitis in Diabetic Ketoacidosis: A Rare Clinical Tetrad.

Splenic Vein Thrombosis Complicating Hypertriglyceridemia-Induced Acute Pancreatitis in Diabetic Ketoacidosis: A Rare Clinical Tetrad.

Journal: Cureus

Published: August 26, 2026

Antithrombotic therapy to minimize total events after ACS or PCI in atrial fibrillation: insights from AUGUSTUS.

Antithrombotic therapy to minimize total events after ACS or PCI in atrial fibrillation: insights from AUGUSTUS.

Journal: Current opinion in cardiology

Published: August 19, 2026

Apixaban Lead-In Versus Lead-In Omission in Hospitalized Adults with Acute Venous Thromboembolism: A Retrospective Safety Analysis.

Apixaban Lead-In Versus Lead-In Omission in Hospitalized Adults with Acute Venous Thromboembolism: A Retrospective Safety Analysis.

Journal: Hospital pharmacy

Published: August 19, 2026

Reduced Versus Full Lead-In Apixaban or Rivaroxaban in Acute Venous Thromboembolism: A Systematic Review.

Reduced Versus Full Lead-In Apixaban or Rivaroxaban in Acute Venous Thromboembolism: A Systematic Review.

Journal: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Published: August 18, 2026

Not all that glitters is gold. Is this the end of andexanet, the antidote to rivaroxaban and apixaban?

Not all that glitters is gold. Is this the end of andexanet, the antidote to rivaroxaban and apixaban?

Journal: Medicina

Published: August 16, 2026

Drug-induced liver injury (DILI)

Drug-induced liver injury (DILI)

Journal: Praxis

Published: August 13, 2026

Efficacy of direct oral anticoagulants in the prophylaxis of catheter-related thrombosis: The DOACAT study.

Efficacy of direct oral anticoagulants in the prophylaxis of catheter-related thrombosis: The DOACAT study.

Journal: The journal of vascular access

Published: August 09, 2026

Showing 1-12 of 6,675

Last Updated: 09/19/2026